25K0.F Karyopharm Therapeutics Inc.
- Market cap
- EUR 454K
- P/E
- -
- P/B
- 12.71x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 25K0.F undervalued?
Graham numberThe Graham number of Karyopharm Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Karyopharm Therapeutics Inc. fundamental analysis
No fundamental analysis for Karyopharm Therapeutics Inc. yet.
Karyopharm Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and…
Full company profileKaryopharm Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Karyopharm Therapeutics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 210M | 157M | 146M | 145M | 146M | 137M |
| Gross Profit | 206M | 152M | 141M | 139M | 140M | 132M |
| Operating Income | -98.3M | -142M | -130M | -119M | -90.7M | -98.6M |
| EBITDA | - | -139M | -118M | -38.6M | -150M | -127M |
| Net Income | -124M | -165M | -143M | -76.4M | -196M | -179M |
| EPS | -25 | -22 | -19 | -9.08 | -11 | -7.88 |
| Balance Sheet | ||||||
| Total Assets | 305M | 358M | 240M | 164M | 108M | 111M |
| Total Liabilities | 385M | 375M | 377M | 350M | 401M | 441M |
| Shareholders' Equity | -79.7M | -16.7M | -136M | -186M | -293M | -330M |
| Cash & Short-term Investments | 190M | 135M | 52.2M | 62.5M | 60.5M | 55.0M |
| Cash Flow | ||||||
| Operating Cash Flow | -107M | -150M | -92.7M | -127M | -75.4M | -95.3M |
| Capital Expenditure | 5.71M | 118K | 0.00 | 142K | 0.00 | 0.00 |
| Free Cash Flow | -113M | -150M | -92.7M | -128M | -75.4M | -95.3M |
| Ratios | ||||||
| ROA | -40.6% | -46.1% | -59.5% | -46.5% | -180.8% | -160.6% |
| Net Profit Margin | -59.1% | -105.2% | -98.0% | -52.6% | -134.2% | -130.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Karyopharm Therapeutics Inc. dividends
Karyopharm Therapeutics Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:15 on Feb 26, 2025.
Who owns Karyopharm Therapeutics Inc.
- Insiders 4.65%
- Institutions 95.13%
- Public & others 0.22%
- Shares outstanding 22.7M
- Free float 18.6M
Karyopharm Therapeutics Inc. company profile
- Company name
- Karyopharm Therapeutics Inc.
- Ticker
- 25K0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 228
- Fiscal year end
- December
- Address
- 85 Wells Avenue, Newton, MA, United States, 02459-3298
- Phone
- 617 658 0600
- Website
- karyopharm.com
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. On November 2, 2026, Karyopharm Therapeutics Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court f
Karyopharm Therapeutics Inc. management
10- Mr. Richard A. Paulson M.B.A.President, CEO & Director · born 1967
- Mr. Stuart PoultonExecutive VP & Chief Development Officer · born 1973
- Dr. Reshma Rangwala M.D., Ph.D.Executive VP, Chief Medical Officer & Head of Research · born 1978
- Dr. Sharon Shacham M.B.A., Ph.D.Co-Founder & Chairman of Scientific Advisory Board · born 1970
- Ms. Kristin AbateVP, Chief Accounting Officer & Assistant Treasurer
- Mr. Michael J. Mano J.D.Executive VP, Chief Legal Officer & Secretary · born 1977
- Mr. James Accumanno J.D.Chief Compliance Officer
- Ms. Lisa DiPaoloExecutive VP & Chief Human Resource Officer
- Mr. Brian Austad Ph.D.Senior Vice President of Pharmaceutical Sciences
- Ms. Sohanya Cheng M.B.A.Executive VP, Chief Commercial Officer & Head of Business Development · born 1983